106910-77-4

Basic information

• Product Name: D-N-Benzylserine
• Synonyms: D-N-Benzylserine;N-(phenylmethyl)-D-Serine
• CAS NO: 106910-77-4
• Molecular Formula: C₁₀H₁₃NO₃
• Molecular Weight: 195.21512
• Mol File: 106910-77-4.mol

Chemical Properties

• Melting Point: 235-237 °C
• Boiling Point: 405.6°C at 760 mmHg
• Flash Point: 199.1°C
• Appearance: /
• Density: 1.246g/cm³
• Vapor Pressure: 2.63E-07mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.16±0.10(Predicted)
• CAS DataBase Reference: D-N-Benzylserine(CAS DataBase Reference)
• NIST Chemistry Reference: D-N-Benzylserine(106910-77-4)
• EPA Substance Registry System: D-N-Benzylserine(106910-77-4)

Safety Data

• Hazardous Substances Data: 106910-77-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
D-N-Benzylserine is used as a key building block for the synthesis of various pharmaceuticals and biologically active molecules. Its unique structure allows it to be incorporated into the design of new drugs, potentially leading to the development of novel therapeutic agents.
Used in Medicinal Chemistry Research:
D-N-Benzylserine is utilized as a valuable tool in medicinal chemistry research, where it can be used to explore the structure-activity relationships of various compounds and identify potential drug candidates.
Used in Drug Discovery Research:
D-N-Benzylserine serves as a precursor in drug discovery research, enabling the development of new drugs with improved pharmacological properties and therapeutic potential.
Used in Enzyme Inhibition:
D-N-Benzylserine has been studied for its potential as an enzyme inhibitor, which can be useful in the development of drugs targeting specific enzymes involved in disease processes.

InChI:InChI=1/C10H13NO3/c12-7-9(10(13)14)11-6-8-4-2-1-3-5-8/h1-5,9,11-12H,6-7H2,(H,13,14)/t9-/m1/s1

Upstream product

• 100-52-7 benzaldehyde 
• 5874-57-7 R-(-)-serine methyl ester hydrochloride 
• 312-84-5 D-Serine 
• 515156-88-4 N-benzyl-D-serine 
• 56-45-1 L-serin 
• 106910-76-3 (RS)-N-benzylserine 
• 123639-56-5 (S)-N-benzylserine methyl ester 
• 100-44-7 benzyl chloride 
• 17136-44-6 N-benzyl-L-serine methyl ester hydrochloride 
• 100-46-9 benzylamine 

Downstream Products

• 385802-30-2 (3S)-5-oxo-N,4-bis(phenylmethyl)-3-morpholinecarboxamide 
• 714971-27-4 (R)-(4-benzylmorpholin-3-yl)methanol hydrochloride 
• 1089280-12-5 ethyl oxo((phenylmethyl){[(3S)-4-(phenylmethyl)-3-morpholinyl]methyl}amino)acetate 
• 1152110-17-2 1-phenyl-N-{[(3S)-4-(phenylmethyl)-3-morpholinyl]methyl}methanamine 
• 1089280-09-0 (3R)-5-oxo-N,4-bis(phenylmethyl)-3-morpholinecarboxamide 
• 106973-39-1 ethyl (R)-4-benzyl-5-oxomorpholine-3-carboxylate 
• 101376-25-4 (S)-4-benzyl-3-(hydroxymethyl)morpholine 
• 106910-85-4 ethyl (R)-4-benzylmorpholine-3-carboxylate 
• 106973-36-8 (3R)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 
• 917572-28-2 (S)-4-benzyl-3-(chloromethyl)morpholine 
• 106910-79-6 (RS)-4-benzyl-5-oxomorpholine-3-carboxylic acid 
• 132958-54-4 N-benzyl-(2S)-oxo-1,2,3-oxathiazolidine-(4S)-carboxylic acid tert-butyl ester 
• 132903-69-6 N-benzyl-(2R)-oxo-1,2,3-oxathiazolidine-(4S)-carboxylic acid tert-butyl ester 
• 132903-76-5 (S)-2-Benzylamino-3-(tert-butyl-dimethyl-silanyloxy)-propionic acid tert-butyl ester 

Relevant articles and documents

Selenoimidazolium Salts as Supramolecular Reagents for Protein Alkylation

Se-benzyl selenoimidazolium salts are characterized by remarkable alkyl-transfer potential under physiological conditions. Structure-activity relationship studies show that selective monoalkylation of primary amines depends on supramolecular interactions

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

Controlling the self-assembly of homochiral coordination architectures of CuII by substitution in amino acid based ligands: Synthesis, crystal structures and physicochemical properties

Through the strategic design of ligands based on amino acids, structural diversity in chiral coordination architectures of CuII is demonstrated with six new examples: {[Cu(l-HTyrbenz)2]·CH3OH·H2O}n (1), {[Cu(l-HSerbenz)2]·3H2O}n (2), {[Cu(l-HTyrthio)2]·H2O}n (3), [Cu(l-HTyr4-pyr)2(H2O)]·2H2O (4), [Cu(l-HSerthio)2(H2O)] (5), and [Cu(l-Phethio)2(H2O)]·3H2O (6) [where l-H2Tyrbenz = l-N-(benzyl)-tyrosine, l-H2Serbenz = l-N-(benzyl)-serine, l-H2Tyrthio = l-N-(methyl-2-thiophenyl)-tyrosine, l-H2Tyr4-pyr = l-N-(methyl-4-pyridyl)-tyrosine, l-H2Serthio = l-N-(methyl-2-thiophenyl)-serine and l-HPhethio = l-N-(methyl-2-thiophenyl)-phenylalanine]. For these 1:2 metal-ligand complexes, the availability of a donor atom (either from the phenolic OH group or the carboxylate group of one of the ligands) for bridging between the CuII centers results in the formation of coordination polymers (1-3), while no such availability allows a water molecule to occupy the fifth site around the CuII center to generate hydrogen bonded supramolecular assemblies (4-6). In 1, a coordination polymer is formed via a syn-anti bridging carboxylate, and the phenolic group has no role in its formation. To further emphasize this point, l-tyrosine in 1 is replaced with l-serine to form 2, in which an anti-anti bridging by the carboxylate group is observed. On the other hand, the formation of {[Cu(l-HTyrthio)2]·H2O}n (3) results from the growth of a spiral polymer via the unique phenolic bridging with a distance of 10.806(9) ? between two CuII centers. On changing from the l-H2Tyrbenz ligand to the l-H2Tyr4-pyr ligand (1vs.4), the strong hydrogen bonding of the pyridyl nitrogen with the phenolic group does not allow the latter to bind to CuII. Similarly, on changing from l-H2Tyrthio to l-H2Serthio (3vs.5), the length of the -CH2OH group in the latter is much less than the distance between the two CuII centers, therefore this group cannot occupy the fifth site and thus a water molecule is coordinated. This is further confirmed by reacting 5 with 2 eq. of l-H2Tyrthio in methanol to form 3, while the reverse is not possible. All these compounds are characterized by a number of analytical methods, such as elemental analysis, FTIR, UV-Vis and circular dichroism spectroscopy, polarimetry, powder and single crystal X-ray diffraction and thermogravimetric analysis. Photoluminescence properties of all ligands containing the l-tyrosine group and their metal complexes (1, 3 and 4) are compared in solution at room temperature. This journal is

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3- oxopropyl}hydroxyformamide compounds of Formula (I): or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity and in treatment methods for bacterial infections

Fused Thiazole Derivatives As Kinase Inhibitors

A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS

A series of fused bicyclic thiazole and thiophene derivatives which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, and in the 4-position by hydroxy, oxo or an amine moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. (I)

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H- indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epide

Structure-activity relationships in a series of 4-[1H-indazol-5-ylamino] pyrrolo[2,1-f][1,2,4]triazine-6-carbamates identified dual human epidermal growth factor receptor (HER)1/HER2 kinase inhibitors with excellent biochemical potency and kinase selectiv

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.